1. Home
  2. PARK vs ENTX Comparison

PARK vs ENTX Comparison

Compare PARK & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PARK

Park Dental Partners Inc.

N/A

Current Price

$17.17

Market Cap

70.6M

Sector

Health Care

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.09

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PARK
ENTX
Founded
1972
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.6M
74.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
PARK
ENTX
Price
$17.17
$1.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
26.9K
104.1K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
N/A
$181,000.00
Revenue This Year
$7.06
N/A
Revenue Next Year
$6.17
N/A
P/E Ratio
$6.47
$6.22
Revenue Growth
N/A
N/A
52 Week Low
$12.29
$1.00
52 Week High
$21.60
$3.22

Technical Indicators

Market Signals
Indicator
PARK
ENTX
Relative Strength Index (RSI) 47.18 36.00
Support Level $14.41 $1.09
Resistance Level $21.33 $1.61
Average True Range (ATR) 1.26 0.17
MACD -0.29 -0.02
Stochastic Oscillator 29.87 18.63

Price Performance

Historical Comparison
PARK
ENTX

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: